Form 4: Orchestra BioMed CEO David Hochman Acquires 4,000 Shares

Orchestra BioMed's CEO, David Hochman, purchased 4,000 shares of common stock at an average price of $4.66 on December 23, 2024.

Summary

• David Hochman, CEO of Orchestra BioMed Holdings, Inc., acquired 4,000 shares of common stock on December 23, 2024.
• The shares were purchased at a weighted average price of $4.66, with individual transaction prices ranging from $4.60 to $4.75.
• Following the transaction, Mr. Hochman directly owns 579,498 shares of common stock.
• He also indirectly owns 335,002 shares through the DPH 2008 Trust, 2,000 shares each through the Solomon Ascher Hochman 2019 Trust, the Hannah Hochman 2019 Trust, and the Judah Herman Hochman 2019 Trust, and 3,140 shares through the NSH 2008 Family Trust.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the CEO's purchase of shares suggests confidence in the company, but it is a routine transaction and not a major event.

Positives

• The CEO's purchase of shares could be seen as a positive signal of confidence in the company's future prospects.
• The purchase increases the CEO's stake in the company, aligning his interests with those of other shareholders.

Management Comments

• The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Industry Context

Insider trading activity is closely monitored by regulators and investors as it can provide insights into management's view of the company's prospects. This purchase by the CEO is a routine transaction that is required to be disclosed.

Comparison to Industry Standards

• Executive share purchases are common across the industry, and this transaction is within the normal range of such activities.
• It is typical for executives to hold shares both directly and indirectly through trusts or other entities.

Stakeholder Impact

• The share purchase may have a slightly positive impact on shareholder sentiment.
• The transaction does not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Orchestra BioMed, David Hochman, share purchase, insider trading, common stock, executive, CEO, OBIO